Early detection of lung cancer can greatly improve survival rates, but due to cost-effectivity, accessibility and safety issues, screening is only performed in some countries under very specific conditions. In Europe, only 4 countries have implemented a screening program resulting in 75% of patients being detected at late stages and more than 50% of patients dying within 1 year of diagnosis. OncoSwab is a startup founded by Andrea Stephany and Dr. Pablo Lara, and we are developing a point-of-care test that can be performed in various healthcare settings. By making screening more accessible to patients, our goal is to help make early lung cancer detection the rule. The global cancer diagnostics market size is around $160 billion million globally.

News

Milestones/News

15.04.2024 Stablishement and starting of multicentric clinical partnerships - Netherlands (LUMC, Erasmus MC), Spain (multiple), US (Mount Sinai, NYU) and Switzerland (Insespital Bern) to start study with patients with Incidental pulmonary nodules
11.11.2023 Patent application filed with Braunpat
11.11.2023 Patent application filed with Braunpat
10.09.2023 Clinical study approved with 150 patients

Videos and Presentations


OncoSwab Voices: Javier Zulueta, MD (Key Medical Advisor)


OncoSwab Voices: Pablo Lara, PhD (CSO)


OncoSwab Voices: Andrea Stephany, MSc (CEO)


Javier Zulueta, MD (Key medical advisor and in process to be CMO)


Dr. Pablo Lara, Co-founder and CSO


Andrea Stephany, Co-founder & CEO